Angiotensin-Converting Enzyme inhibitors (ACE-i) were originally developed to target hypertension but now have additional clinical indications such as congestive heart failure, left ventricular dysfunction, atherosclerotic vascular disease and diabetic nephropathy [1]. This evidence concerns the gene ACE and congestive heart failure.